Drug intelligence / Profile preview

ENGI-004

Development stage: Unknown
Lead developer: Engimmune Therapeutics
Modality: Recombinant Proteins and Enzymes

Overview

**ENGI-004** is an inhibitory specTR (inspecTR), a novel engineered therapeutic receptor developed by Engimmune Therapeutics AG, designed to target an MHC-related receptor that is overexpressed at barrier sites such as the skin and gastrointestinal tract. It functions by inhibiting immune responses at these epithelial surfaces, potentially addressing inflammatory conditions driven by dysregulated immunity. Currently in early discovery stage for immune system diseases, with specific preclinical or discovery-stage evaluation for ulcerative colitis.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on ENGI-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENGI-004.

Explore the full profile